|
US5736577A
(en)
*
|
1995-01-31 |
1998-04-07 |
Sepracor, Inc. |
Methods and compositions for treating urinary incontinence using optically pure (S)-oxybutynin
|
|
US3864388A
(en)
*
|
1970-12-29 |
1975-02-04 |
Sumitomo Chemical Co |
Alkynyl esters of {60 -alkoxy-{60 -phenyl alkenoic acid
|
|
US5036107A
(en)
*
|
1986-06-27 |
1991-07-30 |
Marion Merrell Dow Inc. |
1,7-substituted heptyn-2-ones and use
|
|
US4957941A
(en)
*
|
1987-11-16 |
1990-09-18 |
United Pharmaceuticals, Inc. |
Anti-spasmdoic agents having an acetylenic bond
|
|
IL91377A
(en)
*
|
1988-09-14 |
1996-09-12 |
Nippon Shinyaku Co Ltd |
Derivatives of botinylamine glycolate
|
|
US5677346A
(en)
*
|
1995-01-31 |
1997-10-14 |
Sepracor, Inc. |
Treating urinary incontinence using (S)-desethyloxybutynin
|
|
US5532278A
(en)
*
|
1995-01-31 |
1996-07-02 |
Sepracor, Inc. |
Methods and compositions for treating urinary incontinence using optically pure (S)-oxybutynin
|
|
AU3799997A
(en)
*
|
1996-07-09 |
1998-02-02 |
Sepracor, Inc. |
Dextrorotatory isomers of oxybutynin and desethyloxybutynin in the treatment of gastrointestinal hyperactivity
|
|
US5973182A
(en)
*
|
1998-10-22 |
1999-10-26 |
Sepracor Inc. |
Carbonate Intermediates useful in the preparation of optically active cyclohexylphenylglycolate esters
|
|
US6140529A
(en)
*
|
1998-10-22 |
2000-10-31 |
Sepracor Inc. |
Synthesis of optically active cyclohexylphenylglycolate esters
|
|
DK1280486T3
(da)
*
|
2000-04-26 |
2011-02-14 |
Watson Pharmaceuticals Inc |
Minimering af bivirkning forbundet med oxybutinin-terapi
|
|
US7179483B2
(en)
|
2000-04-26 |
2007-02-20 |
Watson Pharmaceuticals, Inc. |
Compositions and methods for transdermal oxybutynin therapy
|
|
MY130316A
(en)
|
2001-10-26 |
2007-06-29 |
Pharmacia & Upjohn Co Llc |
Quaternary ammonium compounds
|
|
AU2002345266B2
(en)
|
2002-07-08 |
2009-07-02 |
Ranbaxy Laboratories Limited |
3,6-disubstituted azabicyclo [3.1.0]hexane derivatives useful as muscarinic receptor antagonists
|
|
US7265147B2
(en)
*
|
2002-07-31 |
2007-09-04 |
Ranbaxy Laboratories Limited |
3,6-disubstituted azabicyclo [3.1.0]hexane derivatives useful as muscarinic receptor antagonists
|
|
US7410993B2
(en)
*
|
2002-08-09 |
2008-08-12 |
Ranbaxy Laboratories Limited |
3,6-disubstituted azabicyclo [3.1.0] hexane deriviatives useful as muscarinic receptor antagonists
|
|
CN1688544A
(zh)
*
|
2002-08-23 |
2005-10-26 |
兰贝克赛实验室有限公司 |
作为蕈毒碱受体拮抗剂的含氟代和磺酰氨基的3,6-二取代的氮杂双环(3.1.0)己烷衍生物
|
|
TW200412945A
(en)
|
2002-10-25 |
2004-08-01 |
Upjohn Co |
Quaternary ammonium compounds
|
|
DE60227576D1
(de)
|
2002-12-10 |
2008-08-21 |
Ranbaxy Lab Ltd |
3,6-DISUBSTITUIERTE AZABICYCLO i3.1.0 -HEXANDERIVATIVE ALS ANTAGONISTEN DES MUSCARINREZEPTORS
|
|
US7501443B2
(en)
*
|
2002-12-23 |
2009-03-10 |
Ranbaxy Laboratories Limited |
Flavaxate derivatives as muscarinic receptor antagonists
|
|
WO2004056767A1
(en)
*
|
2002-12-23 |
2004-07-08 |
Ranbaxy Laboratories Limited |
1-substituted-3-pyrrolidine derivatives as muscarinic receptor antagonists
|
|
US7488748B2
(en)
|
2003-01-28 |
2009-02-10 |
Ranbaxy Laboratories Limited |
3,6-Disubstituted azabicyclo hexane derivatives as muscarinic receptor antagonists
|
|
WO2004089898A1
(en)
*
|
2003-04-09 |
2004-10-21 |
Ranbaxy Laboratories Limited |
Substituted azabicyclo hexane derivatives as muscarinic receptor antagonists
|
|
AU2003223010A1
(en)
|
2003-04-10 |
2004-11-01 |
Ranbaxy Laboratories Limited |
Substituted azabicyclo hexane derivatives as muscarinic receptor antagonists
|
|
EP1615634B1
(en)
*
|
2003-04-10 |
2007-05-16 |
Ranbaxy Laboratories, Ltd. |
Substituted azabicyclo hexane derivatives as muscarinic receptor antagonists
|
|
CN100436414C
(zh)
*
|
2003-04-11 |
2008-11-26 |
兰贝克赛实验室有限公司 |
作为毒蕈碱受体拮抗剂的氮杂双环衍生物
|
|
US20080319002A1
(en)
*
|
2004-06-16 |
2008-12-25 |
Ranbaxy Laboratories Limited |
Xanthine Derivatives a Useful as Muscarinic Receptor Antagonists
|
|
US20080262075A1
(en)
*
|
2004-08-19 |
2008-10-23 |
Ranbaxy Laboratories Limited |
Pyrrolidine Derivatives as Muscarinic Receptor Antagonists
|
|
US20080280883A1
(en)
*
|
2004-09-24 |
2008-11-13 |
Mohammad Salman |
Muscarinic Receptor Antagonists
|
|
WO2006035303A1
(en)
*
|
2004-09-29 |
2006-04-06 |
Ranbaxy Laboratories Limited |
Muscarinic receptor antagonists
|
|
US20100016400A1
(en)
*
|
2004-11-19 |
2010-01-21 |
Naresh Kumar |
Azabicyclic muscarinic receptor antagonists
|
|
US20100035954A1
(en)
*
|
2004-12-15 |
2010-02-11 |
Mohammad Salman |
Acid addition salts of muscarinic receptor antagonists
|
|
US20080319043A1
(en)
*
|
2005-05-03 |
2008-12-25 |
Mohammad Salman |
3,6-Disubstituted Azabicyclo (3.1.0) Hexane Derivatives as Muscarinic Receptor Antagonists
|
|
US20090221664A1
(en)
|
2005-10-19 |
2009-09-03 |
Abhijit Ray |
Pharmaceutical compositions of muscarinic receptor antagonists
|
|
US20090010923A1
(en)
*
|
2007-04-24 |
2009-01-08 |
University Of Maryland, Baltimore |
Treatment of cancer with anti-muscarinic receptor agents
|
|
US20110087042A1
(en)
*
|
2008-02-04 |
2011-04-14 |
Matrix Laboratories Limited |
Crystalline oxybutynin and process for preparing the same
|
|
US8748433B2
(en)
|
2010-04-30 |
2014-06-10 |
Merck Sharp & Dohme Corp. |
β3 adrenergic receptor agonists
|
|
PH12013500221A1
(en)
|
2010-08-03 |
2017-08-23 |
Altherx Inc |
Combinations of beta - 3 adrenergic receptor agonists and muscarinic receptor antagonists for treating overactive bladder
|
|
US9907767B2
(en)
|
2010-08-03 |
2018-03-06 |
Velicept Therapeutics, Inc. |
Pharmaceutical compositions and the treatment of overactive bladder
|
|
WO2013119910A1
(en)
|
2012-02-09 |
2013-08-15 |
Altherx, Inc. |
Combination of muscarinic receptor antagonists and beta- 3 adrenoceptor agonists for treating overactive bladder
|
|
WO2016090168A1
(en)
|
2014-12-03 |
2016-06-09 |
Velicept Therapeutics, Inc. |
Compositions and methods of using modified release solabegron for lower urinary tract symptoms
|
|
WO2017070689A2
(en)
|
2015-10-23 |
2017-04-27 |
Velicept Therapeutics, Inc. |
Solabegron zwitterion and uses thereof
|
|
MD3746126T2
(ro)
|
2018-01-30 |
2024-12-31 |
Apnimed Inc Delaware |
Metode și compoziții pentru tratamentul apneei în somn sau sforăitului simplu
|
|
EP4146621A1
(en)
|
2020-05-05 |
2023-03-15 |
Apnimed, Inc. (Delaware) |
Polymorphic forms of (r)-oxybutynin hydrochloride
|